| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 15/06/2022 | 17:36 | Edgar (US Regulatory) | Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25) | NYSE:OACB | Oaktree Acquisition Corp II |
| 09/06/2022 | 13:10 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NYSE:OACB | Oaktree Acquisition Corp II |
| 09/06/2022 | 03:16 | Business Wire | Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss | NYSE:OACB | Oaktree Acquisition Corp II |
| 08/06/2022 | 11:54 | Business Wire | Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises | NYSE:OACB | Oaktree Acquisition Corp II |
| 07/06/2022 | 22:00 | Business Wire | Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination | NYSE:OACB | Oaktree Acquisition Corp II |
| 03/06/2022 | 23:29 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:OACB | Oaktree Acquisition Corp II |
| 03/06/2022 | 23:17 | Business Wire | Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech | NYSE:OACB | Oaktree Acquisition Corp II |
| 24/05/2022 | 13:00 | Business Wire | Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara® | NYSE:OACB | Oaktree Acquisition Corp II |
| 16/05/2022 | 21:08 | Edgar (US Regulatory) | Quarterly Report (10-q) | NYSE:OACB | Oaktree Acquisition Corp II |
| 16/05/2022 | 14:00 | Business Wire | Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara® | NYSE:OACB | Oaktree Acquisition Corp II |
| 11/05/2022 | 14:00 | Business Wire | Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination | NYSE:OACB | Oaktree Acquisition Corp II |
| 11/05/2022 | 00:34 | Edgar (US Regulatory) | Proxy Statement - Merger or Acquisition (definitive) (defm14a) | NYSE:OACB | Oaktree Acquisition Corp II |
| 20/04/2022 | 23:00 | Business Wire | Alvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQ | NYSE:OACB | Oaktree Acquisition Corp II |
| 20/04/2022 | 18:45 | Business Wire | Alvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-Notierung | NYSE:OACB | Oaktree Acquisition Corp II |
| 20/04/2022 | 14:15 | Business Wire | Alvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQ | NYSE:OACB | Oaktree Acquisition Corp II |
| 20/04/2022 | 00:00 | Business Wire | Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange | NYSE:OACB | Oaktree Acquisition Corp II |
| 08/04/2022 | 16:01 | Business Wire | アルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開く | NYSE:OACB | Oaktree Acquisition Corp II |
| 07/04/2022 | 03:15 | Business Wire | Alvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVie | NYSE:OACB | Oaktree Acquisition Corp II |
| 07/04/2022 | 00:21 | Business Wire | Alvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira® | NYSE:OACB | Oaktree Acquisition Corp II |
| 06/04/2022 | 13:00 | Business Wire | Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie | NYSE:OACB | Oaktree Acquisition Corp II |
| 14/03/2022 | 12:10 | Business Wire | アルヴォテックがアッヴィとの米国特許・企業秘密紛争を解決し、Humira®向けにアルヴォテックが提案中の高濃度バイオシミラー（AVT02）の米国での権利を確保 | NYSE:OACB | Oaktree Acquisition Corp II |
| 09/03/2022 | 23:44 | Business Wire | Alvotech legt US-Patent- und Geschäftsgeheimnisstreitigkeiten mit AbbVie bei und sichert sich US-Rechte für von Alvotech geplantes hochkonzentriertes Biosimilar (AVT02) zu Humira® | NYSE:OACB | Oaktree Acquisition Corp II |
| 09/03/2022 | 18:03 | Business Wire | Alvotech règle les litiges portant sur des brevets et des secrets commerciaux qui l’opposaient à AbbVie aux États-Unis et garantit ainsi les droits américains pour le biosimilaire à l’Humira® haute concentration (AVT02) proposé par Alvotech | NYSE:OACB | Oaktree Acquisition Corp II |
| 08/03/2022 | 23:06 | Business Wire | Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira® | NYSE:OACB | Oaktree Acquisition Corp II |
| 16/02/2022 | 22:14 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NYSE:OACB | Oaktree Acquisition Corp II |
| 07/02/2022 | 22:46 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NYSE:OACB | Oaktree Acquisition Corp II |
| 20/01/2022 | 16:15 | Business Wire | Alvotech augmente le montant de transaction PIPE sursouscrite qui s’approche désormais de 175 millions USD | NYSE:OACB | Oaktree Acquisition Corp II |
| 19/01/2022 | 17:18 | Business Wire | Alvotech vergrößert überzeichnete PIPE-Transaktion auf ca. 175 Mio. USD | NYSE:OACB | Oaktree Acquisition Corp II |
| 18/01/2022 | 22:01 | Business Wire | Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million | NYSE:OACB | Oaktree Acquisition Corp II |
| 13/12/2021 | 22:10 | Edgar (US Regulatory) | Amended Quarterly Report (10-q/a) | NYSE:OACB | Oaktree Acquisition Corp II |
